awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q36448699-0F48E413-B8F2-4473-B2E4-8641930C1508
Q36448699-0F48E413-B8F2-4473-B2E4-8641930C1508
BestRank
Statement
http://www.wikidata.org/entity/statement/Q36448699-0F48E413-B8F2-4473-B2E4-8641930C1508
Second-line treatment of postmenopausal women with advanced breast carcinoma.
P2860
Q36448699-0F48E413-B8F2-4473-B2E4-8641930C1508
BestRank
Statement
http://www.wikidata.org/entity/statement/Q36448699-0F48E413-B8F2-4473-B2E4-8641930C1508
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
ae138605ca05ebbe38f34702dc04c2114262c000
P2860
The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells.